VHL gene mutations in renal cell carcinoma: role as a biomarker of disease outcome and drug efficacy.
The therapeutic landscape for renal cell carcinoma (RCC) has changed drastically over the past several years with the emergence of molecularly targeted therapies. With previous prognostic and predictive tools based on studies of patients treated with cytokine therapies, confirmation of these prior methods and discovery of new markers in this new era of targeted therapy are of great importance. Alteration of the von Hippel-Lindau gene (VHL) by mutation, loss of heterozygosity, and promoter methylation has been found to be important to RCC pathogenesis. In this review, we discuss the potential role of VHL mutation as a prognostic and predictive marker for RCC.
Cowey
C Lance
CL
Lineberger Cancer Center, 450 West Drive, CB 7295, Chapel Hill, NC 27599, USA.
Rathmell
W Kimryn
WK
D014408:Biomarkers, Tumor; D002292:Carcinoma, Renal Cell / Q000188:drug therapy / Q000235:genetics*; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000235:genetics*; D009154:Mutation; D011379:Prognosis; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D051794:Von Hippel-Lindau Tumor Suppressor Protein / Q000235:genetics*
D014408:Biomarkers, Tumor; D042461:Vascular Endothelial Growth Factor A; D051794:Von Hippel-Lindau Tumor Suppressor Protein